
The clinical administration of the blood component plasma from recovered Covid-19 patients to those severely affected by the disease could be a safe option without adverse side effects, according to a study which may lead to better treatment protocols against novel coronavirus infection.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2AydL56
via
IFTTT
0 comments:
Post a Comment